Related Experiment Video
Updated: Jul 14, 2026

A Rat Model of Tibial Cortex Transverse Transport for the Treatment of Lower Limb Ischemia
Published on: March 6, 2026
Medical therapy for intermittent claudication.
1Department of Surgery, Derby Hospitals NHS Foundation Trust, University of Nottingham, UK.
Cilostazol, a phosphodiesterase III inhibitor, effectively improves walking distance and quality of life for intermittent claudication patients. This review synthesizes evidence from trials of cilostazol and explores therapeutic angiogenesis for peripheral arterial disease.
Area of Science:
- Vascular Medicine
- Pharmacology
Background:
- Intermittent claudication (IC) management involves lifestyle changes, surgery, and medical therapy.
- Medical therapy aims to improve symptoms, stabilize vascular disease, and enhance lower limb outcomes.
Observation:
- Randomized controlled trials demonstrate cilostazol (100mg twice daily) improves pain-free and maximum walking distances.
- Cilostazol enhances quality of life in IC patients without tissue necrosis or rest pain.
Findings:
- This review summarizes 8 pivotal trials of cilostazol involving over 2000 IC patients over 6 months.
- Evidence for other intermittent claudication symptom relief modalities is less robust.
- Therapeutic angiogenesis is an area of interest for promoting new vessel formation in peripheral arterial disease.
Implications:
- Cilostazol is an effective medical therapy for intermittent claudication, improving functional capacity and quality of life.
- Further research into therapeutic angiogenesis holds promise for enhancing lower limb collateralization in peripheral arterial disease.
More Related Videos
14:52Computerized Dynamic Posturography for Postural Control Assessment in Patients with Intermittent Claudication
Published on: December 11, 2013
10:50Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging
Published on: June 29, 2013
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Atherosclerosis III: Management
Peripheral Artery Disease IV: Nursing Management
Coronary Artery Disease V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...